Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 2
---
4,000,000 Shares of Common Stock Up to 8,000,000 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants and Common Warrants We are offering up to 4,000,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), together with 4,000,000 new common warrants (the “Offered Common Warrants”) to purchase up to an aggregate of 4,000,000 shares of our Common Stock and an aggregate of 4,000,000 shares of our Common Stock issuable upon exercise of the Offered Common Warrants. Each share of Common Stock, or pre-funded warrant in lieu thereof (“Pre-Funded Warrants”), is being sold together with an Offered Common Warrant to purchase one share of Common Stock. The assumed public offering price for each share of Common Stock and accompanying Offered Common Warrant is $2.00, which was the closing price of our Common Stock on the Nasdaq Capital Market (the “Nasdaq”) on February 3, 2025. Each Offered Common Warrant will have an exercise price per share of $[ ] and will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Offered Common Warrants (the “Warrant Stockholder Approval”), provided, however, if (i) the Offering is deemed a public offering or (ii) the Pricing Conditions (as defined below) are met, the Warrant Stockholder Approval will not be required and the Warrant will be exercisable upon issuance (the “Initial Exercise Date”). As used herein “Pricing Conditions” means that the combined public offering price per share and accompanying Offered Common Warrants is such that the Warrant Stockholder Approval is not required under the rules of Nasdaq because either (i) the offering is an at-the-market offering under Nasdaq rules and such price equals or exceeds the sum of (a) the applicable “Minimum Price” per share under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of Common Stock underlying the Offered Common Warrants or (ii) the offering is a discounted offering where the pricing and discount (including attributing a value of $0.125 per whole share underlying the Offered Common Warrants) meet the pricing requirements under Nasdaq’s rules. The Offered Common Warrants will expire on the 5-year anniversary of the Initial Exercise Date